First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Study
![ReachMD Healthcare Image](https://cdn.practicaldermatology.com/cache/5d/ec/5decf1af90766edb42d5793c549bf7bd.jpg 1x, https://cdn.practicaldermatology.com/cache/2e/be/2ebe15721d33ee47ec81969f07362cfe.jpg 2x)
The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea.
This clinical trial, DMT210-003, is a 12-week, Phase 2, multi-center, double-blind, vehicle controlled study designed to evaluate the safety, tolerability and efficacy of twice daily dosing of DMT210 in approximately 104 moderate to severe acne rosacea patients.
Dermata expects to have top-line results in the second half of 2017.